This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): SR-45023A
Description: APOMINE is a non-hormonal agent known as a phosphonate ester. It is orally bioavailable and has been shown, in preclinical models, to inhibit osteoclasts and block bone resorption, like the currently marketed bisphosohonic acids such as Fosamax and Actonel . Unlike the currently marketed drugs, APOMINE appears to activate osteoblasts with potential bone-building effects.
Deal Structure: In October 2010, Sanofi-aventis announced it has commenced a tender offer for all outstanding shares of common stock of Genzyme for $69 per share, net to the seller in cash, without interest and less any required withholding taxes. In April 2011, Sanofi-aventis announced that it successfully completed its exchange offer for all outstanding shares of common stock of Genzyme Corporation.
Pink Sheet Trademark Review
Additional information available to subscribers only: